Last updated: October 16, 2026
Biltricide, Bayer’s U.S. brand of praziquantel, is an established anthelmintic with limited brand-specific financial disclosure, no meaningful remaining exclusivity barrier, and exposure to generic competition. Its commercial outlook is driven by schistosomiasis and tapeworm treatment demand, U.S. prescription volumes, public-health procurement outside the U.S., and pricing pressure from generic praziquantel. Bayer does not separately report Biltricide revenue, so a precise brand-level financial forecast is unavailable. The most supportable view is a mature, defensively positioned product with stable medical demand but limited pricing power.
What is Biltricide and how is it used?
Biltricide is a 600 mg tablet containing praziquantel. The U.S. Food and Drug Administration approved it for the treatment of schistosomiasis caused by several Schistosoma species and infections caused by liver flukes, including Clonorchis and Opisthorchis species. The product is administered orally and is generally dosed according to body weight and parasite species (FDA, 2019).
| Product attribute |
Biltricide position |
| Active ingredient |
Praziquantel |
| Dosage form |
600 mg oral tablet |
| U.S. sponsor |
Bayer HealthCare Pharmaceuticals Inc. |
| FDA application |
NDA 018714 |
| Main indications |
Schistosomiasis and selected liver-fluke infections |
| Regulatory status |
Prescription drug |
| Primary competitors |
Generic praziquantel products and other praziquantel brands |
| Biosimilar relevance |
None; Biltricide is a small-molecule drug |
| Commercial stage |
Mature, post-exclusivity product |
Biltricide is mainly a treatment product rather than a chronic-use medicine. That limits recurring prescription volume per patient. Demand is concentrated in endemic regions, travel medicine, infectious-disease treatment, immigrant health, and public-health programs.
What is the FDA and Orange Book status of Biltricide?
Biltricide remains an FDA-approved prescription product, but its original market exclusivity has expired. The Orange Book is the principal source for current approved-product and patent-listing information. Biltricide’s commercial position does not depend on a current composition-of-matter patent.
The key regulatory facts are:
- The product is approved under NDA 018714.
- The active ingredient, praziquantel, is an established small molecule with extensive generic use.
- FDA approval does not confer current market exclusivity on Bayer.
- Generic approval can proceed through an abbreviated new drug application when the applicant demonstrates pharmaceutical equivalence, bioequivalence, and compliance with FDA manufacturing requirements.
- There is no biosimilar pathway applicable to Biltricide because praziquantel is not a biologic.
The practical implication is that Bayer’s protection comes from brand recognition, supply reliability, prescriber familiarity, distribution, and regulatory know-how rather than from a blocking patent estate.
When does Biltricide lose exclusivity?
Biltricide lost meaningful regulatory and patent exclusivity years ago. The original product is a mature drug, and praziquantel is widely available from generic manufacturers internationally.
No commercially significant future loss-of-exclusivity event is expected. The relevant business event already occurred when generic praziquantel entered the market.
| Exclusivity category |
Biltricide position |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No material current protection identified |
| Orphan-drug exclusivity |
Not the principal commercial protection |
| Composition-of-matter patent |
Expired or no longer commercially blocking |
| Formulation patent |
No material current barrier identified |
| Method-of-use patent |
No material current barrier identified |
| Expected generic entry event |
Historical, not prospective |
| Current pricing protection |
Limited |
A precise historical patent-expiration date for the original product is less relevant to current competition than the fact that generic praziquantel is already established in multiple markets.
What patents protect Biltricide?
The commercially relevant Biltricide patent estate is weak. Praziquantel was discovered and commercialized decades ago, and the active ingredient is no longer protected by a live, blocking composition patent in the principal market.
No current patent category appears capable of preventing generic praziquantel competition in the United States:
Composition patents
Any original composition patent covering praziquantel has expired. Generic manufacturers can therefore develop products containing the same active ingredient, subject to FDA approval requirements.
Formulation patents
Biltricide’s tablet formulation is not known to have a current patent barrier that materially prevents generic substitution. Tablets containing praziquantel are technically established dosage forms. The product’s formulation complexity is low relative to modified-release, injectable, inhaled, or biologic products.
Method-of-use patents
The approved uses for schistosomiasis and liver-fluke infections are longstanding anti-infective indications. No active method-of-use patent is known to provide meaningful commercial exclusivity for Biltricide.
Manufacturing and know-how
Manufacturing know-how can still affect product quality, tablet scoring, stability, taste, supply continuity, and regulatory compliance. Those factors may create operational advantages, but they do not create patent exclusivity.
Are there Paragraph IV challenges or Biltricide patent settlements?
Biltricide is unlikely to face a new commercially important Paragraph IV event because the product has already entered the post-exclusivity generic market. Paragraph IV litigation is most consequential before generic launch, when a listed patent could delay approval or create a 30-month stay. That framework has limited relevance to a mature praziquantel product without a meaningful blocking patent estate.
No material current Biltricide-specific Paragraph IV settlement is identified in the cited public regulatory and company materials. Generic competition is better understood as an established market condition than as an emerging litigation event.
What is the competitive landscape for praziquantel?
The competitive landscape has two distinct segments:
- The U.S. branded prescription market, where Biltricide benefits from brand recognition and established physician use.
- The global public-health market, where generic praziquantel and tender-based procurement dominate.
| Competitive factor |
Effect on Biltricide |
| Generic praziquantel |
Reduces price and substitution power |
| Limited treatment duration |
Restricts repeat demand |
| Endemic disease burden |
Supports long-term volume |
| Public procurement |
Favors low-cost suppliers |
| U.S. brand recognition |
Supports premium positioning in selected channels |
| Product scarcity concerns |
Can support demand for reliable branded supply |
| Pediatric formulation expansion |
May increase total praziquantel access but intensify competition |
| Alternative anthelmintics |
Relevant for some helminth infections, less direct for schistosomiasis |
Praziquantel remains the principal medicine used in large-scale schistosomiasis control programs. The World Health Organization reported that more than 250 million people required preventive chemotherapy for schistosomiasis in 2022, supporting a substantial underlying disease burden (WHO, 2023).
Biltricide does not capture the full global praziquantel opportunity. Much of that demand is served through government programs, nongovernmental organizations, and manufacturers supplying lower-cost products under public tenders.
What is the revenue exposure for Bayer?
Bayer does not separately disclose Biltricide revenue in its annual reporting. It reports businesses at broader segment levels, which prevents a reliable public calculation of product sales, operating margin, or geographic revenue contribution.
The financial exposure can therefore be characterized qualitatively:
| Financial metric |
Public visibility |
| Biltricide annual revenue |
Not separately disclosed |
| Unit volume |
Not separately disclosed |
| Gross margin |
Not separately disclosed |
| U.S. net price |
Not consistently disclosed |
| International sales |
Not separately disclosed |
| Product-level R&D expense |
Not separately disclosed |
| Product-level EBITDA |
Not separately disclosed |
| Bayer segment exposure |
Too broad to isolate Biltricide |
Biltricide is unlikely to be financially material to Bayer relative to the company’s major pharmaceuticals, crop-science products, and consumer-health brands. Its value is more likely associated with dependable cash generation, portfolio breadth, and presence in an established infectious-disease category than with major corporate growth.
What is the financial trajectory for Biltricide?
The likely trajectory is mature and relatively stable, with limited nominal growth.
Base case
The base case is low-single-digit volume movement, offset by generic price pressure and limited ability to raise prices. U.S. demand should remain supported by diagnosed infections, travel-related cases, specialist prescribing, and institutional treatment.
Upside case
An upside scenario would require one or more of the following:
- Higher global schistosomiasis diagnosis and treatment rates.
- Increased public-health financing.
- Expanded use in pediatric populations.
- Supply disruptions among generic suppliers.
- Greater U.S. demand from immigrant health and travel medicine.
- Improved access to praziquantel in underserved markets.
Downside case
The main downside risks are:
- Further generic price erosion.
- Loss of distribution access.
- Public tender substitution.
- Manufacturing interruptions.
- Lower disease-screening rates.
- Increased use of alternative or locally sourced praziquantel products.
- Procurement shifts toward newer pediatric or dispersible formulations.
| Scenario |
Volume |
Price |
Revenue direction |
| Base case |
Stable to modest growth |
Declining or flat |
Flat to low growth |
| Upside case |
Moderate growth |
Stable |
Low- to mid-single-digit growth |
| Downside case |
Decline |
Declining |
Mid-single-digit decline or worse |
This framework is more reliable than a point estimate because Bayer does not publish the product-level data required for a conventional revenue model.
What manufacturing and intellectual-property barriers affect Biltricide?
Manufacturing barriers are moderate, while intellectual-property barriers are low.
Praziquantel is a small molecule with established synthesis and tablet manufacturing methods. Generic suppliers can generally produce the active ingredient and finished dosage form without needing access to proprietary Bayer technology. The most relevant barriers are:
- Active pharmaceutical ingredient quality.
- Control of impurities and polymorphic form.
- Consistent tablet splitting and dose uniformity.
- Stability and packaging.
- Bioequivalence.
- FDA inspection readiness.
- Reliable supply-chain execution.
- Ability to compete in public tenders.
Biltricide tablets have a distinctive scoring configuration that helps facilitate dose administration. That feature may require formulation and manufacturing control, but it does not appear to create a durable patent-based moat.
What licensing deals affect Biltricide?
No major recent licensing transaction has been publicly identified as a central driver of Biltricide’s value. The commercial model is primarily based on Bayer ownership and marketing of the approved product rather than on a visible licensing platform.
The broader praziquantel market has involved public-health partnerships, procurement agreements, and development programs for child-friendly formulations. Those arrangements can increase total praziquantel use without necessarily increasing Biltricide sales, because public-health supply often uses separate manufacturers and products.
What patent litigation affects Biltricide?
No material active patent litigation is identified as a major current risk to Biltricide’s U.S. business. The product’s principal risk is commercial competition, not patent invalidity litigation.
Litigation risk could arise from:
- Product liability claims.
- Manufacturing-quality disputes.
- Distribution or supply contracts.
- Regulatory enforcement.
- Generic-product labeling or bioequivalence disputes.
Those risks differ from the patent litigation profile of newer specialty pharmaceuticals, where Paragraph IV challenges and settlement dates can define market entry.
How does Biltricide compare with newer specialty drugs?
Biltricide has a lower patent risk profile and a lower expected growth profile than newer branded medicines.
| Factor |
Biltricide |
New specialty drug |
| Patent protection |
Minimal or expired |
Often central to valuation |
| Regulatory exclusivity |
Expired |
Potentially active |
| Generic risk |
Already present |
Often prospective |
| Pricing power |
Limited |
Often substantial |
| Clinical demand |
Established, episodic |
May be chronic or expanding |
| R&D burden |
Low at product level |
High |
| Revenue visibility |
Not separately disclosed |
Often modeled from launch data |
| Litigation profile |
Low patent risk |
Frequently material |
Biltricide is therefore better analyzed as a mature branded generic-adjacent product than as a growth pharmaceutical asset.
Key Takeaways
- Biltricide is Bayer’s branded 600 mg praziquantel tablet for schistosomiasis and selected liver-fluke infections.
- FDA approval remains active under NDA 018714.
- Original patent and regulatory exclusivity have expired; generic competition is established.
- No current formulation or method-of-use patent is known to create a meaningful commercial barrier.
- No material current Paragraph IV event or Biltricide-specific patent settlement is identified.
- Bayer does not separately disclose Biltricide revenue, volume, margin, or geographic sales.
- The financial outlook is stable to low-growth, with volume support from persistent disease burden and pressure from generic pricing.
- The principal commercial risks are generic substitution, tender-based procurement, and supply competition.
- There is no biosimilar risk because praziquantel is a small molecule.
- Biltricide’s value is primarily defensive and cash-generative rather than a major driver of Bayer’s growth.
FAQs About Biltricide Market and Patent Risk
Is Biltricide still protected by a patent?
No commercially meaningful patent protection is known to block generic praziquantel competition in the United States. The relevant original protections expired long ago.
Can a generic manufacturer substitute praziquantel for Biltricide?
Generic substitution depends on state pharmacy law, prescriber instructions, product availability, and FDA therapeutic-equivalence determinations. Generic praziquantel competition is already established.
Is Biltricide used in global schistosomiasis campaigns?
Large-scale campaigns generally rely on praziquantel, but public-health procurement often uses generic or specially developed products rather than the U.S. Biltricide brand.
Does Bayer report Biltricide sales separately?
No. Bayer’s public financial reporting does not provide a separate Biltricide revenue line or product-level profitability disclosure.
Could a new pediatric praziquantel product reduce Biltricide demand?
Yes. A child-friendly formulation could increase total praziquantel treatment while shifting some demand away from adult tablets and established branded products.
References
-
Bayer AG. (2024). Annual report 2023. Bayer AG.
-
U.S. Food and Drug Administration. (2019). Biltricide (praziquantel) prescribing information. Bayer HealthCare Pharmaceuticals Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
World Health Organization. (2023). Schistosomiasis: Fact sheet. World Health Organization.
-
World Health Organization. (2023). WHO guideline on control and elimination of human schistosomiasis. World Health Organization.
